This invention is an innovative breakthrough in cancer radiotherapy, offering a cutting-edge solution to address the challenges of radio-resistant and immunosuppressive tumors.
Immune checkpoint blockade, a class of immunotherapy treatment which works by blocking inhibitory receptors on T cells to improve immune responses, has proven to be a remarkable clinical advance in the treatment of many diseases, particularly in cancer.
Stanford researchers in the Lin Lab have identified kinase-modulated bioluminescent indicators (KiMBIs) which can assess real time kinase inhibition in target tissues in vivo.
Researchers at Stanford and the University of Helsinki discovered that a human secretoglobin protein found in sweat gland cells acts as a novel host defense mechanism against Lyme disease.
Wound healing is a huge clinical problem. Problematic outcomes of skin wounds can range from under-healing (e.g., chronic/non-healing wounds) to over-healing (e.g., scarring).
The inventors discovered that a known small molecule tyrosine kinase inhibitor may correct the errant signaling pathways in the rare diseases Hereditary Hemorrhagic Telangiectasia (HHT) and Pulmonary Arterial Hypertension (PAH).
Researchers in the Burns group at Stanford designed a reaction methodology that allows for a green and inexpensive cycloaddition of amine or amide-containing unactivated olefins for the synthesis of biologically relevant cyclobutanes.
Stanford scientists have developed a set of preclinical assays that are specifically designed to detect empathogenic effects of a drug that may indicate applications for that molecule in treating psychiatric diseases like PTSD.
Stanford scientists in Dr. Paul Wender's lab have developed a novel method to synthesize tigilanol tiglate (EBC-46) and related compounds from readily available starting materials.